Results 51 to 60 of about 6,317 (201)

Real-life cost-effectiveness of benralizumab in patients with severe asthma

Respiratory Research, 2021
Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems.
A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon   +10 more
doaj   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma

European Clinical Respiratory Journal
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko   +19 more
doaj   +1 more source

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

, 2019
Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de ...
Alarcón de la Lastra Romero, Catalina, Alegre del Rey, Emilio Jesús, García Mochón, Leticia, Gil Sierra, Manuel David, Sánchez Hidalgo, Marina   +4 more
core   +3 more sources

Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database

Rheumatology &Autoimmunity, EarlyView.
This observational study assessed the association between anti‐type 2 biologic agents and the occurrence of autoimmune diseases using a large real‐world claims database. Anti‐IL‐5 and anti‐IgE therapies were associated with an increased occurrence of autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE ...
Shoichiro Inokuchi
wiley   +1 more source

A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma

Fujita Medical Journal, 2022
Objective: This study aimed to evaluate the predictors of response to benralizumab therapy in patients with refractory bronchial asthma. Methods: After 16 weeks of benralizumab therapy, 32 patients with refractory bronchial asthma were assigned to two
Masahiro Hirose, Kazunobu Kuwabara, Rieko Kondo, Takahiko Horiguchi   +3 more
doaj   +1 more source

Inhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]

, 2018
Peer reviewedPublisher ...
Amaducci, Sandro, Bacci, Elena, Baldacci, Sandra, Bartoli, Maria L., Beghi, Gianfranco M., Benfante, Alida, Brighindi, Sara, Casali, Lucio, Castiglia, Daniela, Cazzola, Mario, Celi, Alessandro, Cianchetti, Silvana, Colombo, Giorgio, Crimi, Claudia, d'Alcontres, Martina Stagno, Dente, Federico L., Di Maria, Annalisa, Di Maria, Giuseppe, Donner, Claudio F., Hui Xin, Shaylynn Yu, Latorre, Manuela, Lavorini, Federico, Maio, Sara, Mannini, Claudia, Messina, Riccardo, Paggiaro, Pier Luigi, Pignatti, Patrizia, Pistolesi, Massimo, Price, David, Scichilone, Nicola, Simoni, Marzia, Spanevello, Antonio, Tan, Shwana, Torchio, Roberto, Viegi, Giovanni, Visca, Dina, Wouters, Emiel F.M.   +36 more
core   +5 more sources

Transcriptomics reveals new regulatory mechanisms involved in benralizumab response [PDF]

, 2023
[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge.
Dávila González, Ignacio Jesús, Estravís Sastre, Miguel, García Sánchez, María Asunción, Gil Melcón, María, Gómez‐García, Manuel, Isidoro García, María, Martín García, Cristina, Moreno‐Jimenez, Emma, Morgado, Natalia, Muñoz Bellido, Francisco Javier, Pérez Pazos, Jacqueline, Ramos González, Jacinto, Sanz Lozano, Catalina Sofía, Triviño, Juan Carlos   +13 more
core   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report

BMC Geriatrics
Background Interleukin-5 (IL-5) has recently been shown to play a crucial role in eosinophil-mediated diseases, implying that an IL-5 receptor alpha chain (IL-5Rα) antibody (benralizumab) can be effective against eosinophilic esophagitis (EoE).
Azusa Ishii, Tomofumi Shibata, Yohei Tsunoda, Takafumi Kayukawa, Masahiro Kobayashi, Masami Orinaka, Shoko Miyamatsu, Yoshio Ryuge, Shuichi Asano, Ichidai Tanaka   +9 more
doaj   +1 more source